Benzimidazole

Benzimidazole

SCHEMBL4359682

[Cr].c1ccc2[nH]cnc2c1.c1ccc2[nH]cnc2c1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
PDPK1 O15530 1/20 0.48
CA12 O43570 1/20 0.48
PARP1 P09874 1/20 0.48
ALOX15 P16050 1/20 0.48
CA9 Q16790 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
PRKCI P41743 1/20 0.48
KDM4E B2RXH2 6/20 0.47
MAPT P10636 2/20 0.47
RAD52 P43351 1/20 0.47
ALDH1A1 P00352 5/20 0.46
HPGD P15428 3/20 0.46
RAB9A P51151 2/20 0.46
QPCT Q16769 2/20 0.46
QPCTL Q9NXS2 2/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
MMP12 P39900 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzimidazole SCHEMBL7214615 1.00 SMN1; SMN2 (0.48) SMN1; SMN2PDPK1CA12PARP1ALOX15
Benzimidazole SCHEMBL29408372 0.97
Benzimidazole SCHEMBL29358377 0.97
Benzimidazole SCHEMBL461969 0.97 SMN1; SMN2 (0.50) SMN1; SMN2PDPK1CA12PARP1ALOX15
Benzimidazole SCHEMBL10931770 0.97 SMN1; SMN2 (0.50) SMN1; SMN2PDPK1CA12PARP1ALOX15
Benzimidazole SCHEMBL6009 0.97
Benzimidazole SCHEMBL23673327 0.95 SMN1; SMN2 (0.48) SMN1; SMN2PDPK1CA12PARP1ALOX15
Benzimidazole SCHEMBL20531480 0.95 SMN1; SMN2 (0.48) SMN1; SMN2PDPK1CA12PARP1ALOX15
Benzimidazole SCHEMBL1304256 0.95 SMN1; SMN2 (0.48) SMN1; SMN2PDPK1CA12PARP1ALOX15
Benzimidazole SCHEMBL21046391 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498390-B2 Chromium complexes and their use in olefin polymerization EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2009-03-03 US disclosed
US-7498287-B2 Chromium complexes and their use in olefin polymerization EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2009-03-03 US disclosed
US-20080071090-A1 Chromium complexes and their use in olefin polymerization KACKER SMITA 2008-03-20 US disclosed
US-20080021181-A1 Chromium complexes and their use in olefin polymerization KACKER SMITA 2008-01-24 US disclosed
US-7297805-B2 Chromium complexes and their use in olefin polymerization EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2007-11-20 US disclosed
EP-1789425-A2 CHROMIUM COMPLEXES AND THEIR USE IN OLEFIN POLYMERIZATION ExxonMobil Research and Engineering Company (US) 2007-05-30 EP disclosed
WO-2006012327-A2 CHROMIUM COMPLEXES AND THEIR USE IN OLEFIN POLYMERIZATION EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2006-02-02 WO disclosed
US-20050288464-A1 Chromium complexes and their use in olefin polymerization EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288464-A1 Chromium complexes and their use in olefin polymerization CBR3, CDYL, CCRL2 SMN1; SMN2 3442/4885PDPK1 3778/4885CA12 224/4885
US-20080071090-A1 Chromium complexes and their use in olefin polymerization CBR3, CDYL, CCRL2 SMN1; SMN2 3442/4885PDPK1 3778/4885CA12 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.